Update on Chemotherapy for Advanced Colorectal Cancer

Size: px
Start display at page:

Download "Update on Chemotherapy for Advanced Colorectal Cancer"

Transcription

1 Review Article [1] March 02, 2001 By Daniel G. Haller, MD [2] Efforts to improve the length and quality of life, as well as to expand treatment options, for patients with metastatic colorectal cancer have only recently become more successful. With Introduction uring the past decade, more changes in the management of colorectal cancer have come about than in the previous half-century of clinical research. Such changes include the establishment of adjuvant treatment for patients with high-risk stage II and III colorectal cancer, in addition to new approaches to managing advanced disease. Previously, there was much nihilism in the management of these patients. This translated into low expectations of benefit from systemic chemotherapy or multimodality approaches, which could possibly extend the life of a patient with metastatic disease and also possibly cure some patients. D The past decade of clinical research in colorectal cancer has also sparked discussion about establishing appropriate end points of clinical benefit from chemotherapy. The gold standard for regulatory approval in the United States is an overall survival advantage with treatment. Previously, only the addition of leucovorin to fluorouracil (5-FU) was approved on this basis. In addition to overall survival, many investigators think that progression-free survival if properly measured could provide a surrogate of treatment effect in clinical trials and also a measure of clinical benefit for patients. This has not been a universally accepted end point, however, and is not currently used for approval of oncologic drugs in the United States. Although clinical investigators have depended on response rates to establish interest in a treatment program, this measure is associated with wide variability and thus may not be dependable for establishing patient benefit, particularly in retrospective analyses. Furthermore, measures of quality of life have generally fallen short of establishing clinical benefit of treatment. It is in the setting of this controversy that new treatments are being assessed, at least one of which has achieved the gold standard for approval in the United States, namely the addition of irinotecan (CPT-11, Camptosar) to fluorouracil (5-FU) and leucovorin for first-line therapy of patients with metastatic colorectal cancer. Fluoropyrimidine Therapy Until recently, various methodologies of systemic 5-FU administration have represented not only the standard of practice but also the standard of care in clinical trials for patients with metastatic disease. The development of optimal treatment programs has been both arduous and long. Ansfield and colleagues reported a phase III trial comparing four different 5-FU regimens in 1977.[1] Results of this early trial suggested that loading course (ie, repetitive daily dosing) 5-FU, with moderate toxicity, was superior to a weekly intravenous (IV) schedule, a nontoxic IV schedule, and an oral schedule. In the latter part of the 20th century, countless patients participated in clinical trials comparing various doses and schedules of 5-FU, with and without new drugs. Perhaps the most significant change in 5-FU use for metastatic colon cancer was the development of biochemically modulated regimens with leucovorin. Leucovorin stabilizes the ternary complex with fluorodeoxyuridine monophosphate (FdUMP) and the enzyme thymidylate synthase. The combination of 5-FU and leucovorin has been compared with bolus 5-FU alone. A meta-analysis of the randomized trials demonstrated a significantly improved response rate with 5-FU and leucovorin but no significant improvement in overall survival.[2] A standard regimen for the treatment of metastatic colorectal cancer has been the Mayo Clinic regimen, in which 5-FU and leucovorin are administered for 5 consecutive days every 4 weeks for Page 1 of 7

2 two cycles, followed by the same regimen every 5 weeks. Results from the first two trials conducted at the Mayo Clinic and the North Central Cancer Treatment Group (NCCTG) showed response rates of 43% and 35%, and median survival times of 12.7 and 9.3 months, respectively.[3,4] With further study, response rates with the Mayo Clinic regimen have ranged from 11% to 19%, and median survival times from 9.2 to 13.1 months.[5-7] Continuous-Infusion vs Bolus 5-FU Both the efficacy and toxicity of 5-FU depend to some degree on the drug dose and schedule and whether leucovorin is administered concurrently. Early in the use of 5-FU, it was observed that the toxicity profile of continuously infused 5-FU was different from that of bolus regimens, eg, decreased myelosuppression and mucositis but increased dermatologic toxicities, including hand-foot syndrome. An early clinical trial by Seifert et al comparing continuously infused 5-FU with bolus injection demonstrated this toxicity difference and also suggested an improved clinical benefit with infusional 5-FU in terms of response and survival rates.[8] A subsequent meta-analysis of six randomized trials of continuously infused 5-FU was published in 1998.[9] Results were similar to those obtained with the addition of leucovorin to 5-FU, with an improvement in response rate from 14% to 22% (P =.0002), but only a marginal improvement in overall survival from 11.3 to 12.1 months (P =.04). The incidence of hematologic toxicity significantly decreased and hand-foot syndrome increased with infusional 5-FU. Many infusional 5-FU regimens are currently in use. One of the first regimens developed is a true continuous-infusion program, in which 5-FU at 300 mg/m2 is administered for more than 4 weeks or until significant toxicity occurs.[10] Alternative regimens have also been developed, including a high-dose 24-hour regimen known as the AIO regimen or Andolan regimen, with 5-FU doses ranging from 2,000 to 2,600 mg/m2.[11] This regimen has also been combined with leucovorin. Results of a large trial comparing the 24-hour infusional regimen, with and without leucovorin, to the Mayo Clinic regimen were recently reported.[12] The findings suggested that the infusional approach improved response rate and time to treatment failure, with an increase in toxicity when leucovorin was added, but with no significant improvement in survival. Another commonly used regimen combines bolus and infusional administration, as devised by de Gramont and colleagues.[5] Bolus 5-FU and leucovorin are administered on the first and second days of a 2-week cycle, with 22-hour 5-FU infusions after each bolus dose. This regimen has been compared directly with a Mayo Clinic-type regimen in which bolus therapy was administered every 4 weeks.[5] A significantly better response rate (32.6% vs 14.4%) and improvement in progression-free survival resulted from the infusion approach; however, overall survival was similar with the two regimens (14.3 vs 13.1 months, P =.067). Infusional approaches, therefore, have not consistently improved overall survival but have been associated with higher response rates, longer time to tumor progression, and a toxicity profile more suitable than that of bolus regimens for combination with myelosuppressive drugs. An open question, which will be addressed in another paper in these proceedings, is whether oral fluoropyrimidines will offer the clinical benefit of infusional 5-FU while also improving patient acceptance. Based on an overview of either biochemically modulated fluorouracil with leucovorin or methotrexate or continuous-infusion 5-FU, there is a consistent trend toward improved response rate with newer regimens using other than bolus 5-FU alone.[2,9] However, the impact on overall survival from these changes has been modest, with an overall survival hazard ratio of 0.90 (0.84, 0.97) compared with bolus 5-FU alone. These data strongly suggest that further studies of fluoropyrimidine therapy alone are unlikely to show the clinical benefit desired for optimal management of metastatic disease. Irinotecan Irinotecan is a topoisomerase I inhibitor that has a mechanism of action different from that of Page 2 of 7

3 fluoropyrimidines. In previously treated colorectal cancer patients, irinotecan at 125 mg/m2 weekly or 350 mg/m2 every 3 weeks resulted in response rates of 15.0% and 12.1%, respectively.[13] This single-agent activity is comparable to that observed in patients treated with fluoropyrimidines. In early phase II trials, the toxicity of single-agent irinotecan included manageable myelosuppression and diarrhea. Although diarrhea may be dose-limiting, in the clinic it is usually quite manageable with aggressive loperamide use. Single-Agent Activity Based on the early phase II data and on the anticipated results of second-line trials of irinotecan in 5-FU-refractory patients, irinotecan was approved in the United States in 1996 for the treatment of colorectal cancer. Approval was initially limited to 5-FU-refractory disease, but results of two further landmark studies led to its approval as for second-line therapy in In the first of these trials, patients who had failed bolus 5-FU therapy were randomly assigned to receive irinotecan plus best supportive care or best supportive care alone.[14] The study end point was improvement in overall survival, which was achieved. Median survival was 9.2 months in the irinotecan-treated group and 6.5 months in the best supportive care alone group (P =.00001). Quality-of-life measures suggested that this improvement in survival was achieved without increasing toxicities significantly. In the second trial, patients who had failed bolus 5-FU were randomly assigned to receive irinotecan or one of three infusional 5-FU regimens.[15] Median survival was 10.8 months in irinotecan-treated patients compared with 8.5 months in fluorouracil-treated patients (P =.035). Based on the known modest activity of infusional 5-FU in patients who have failed bolus therapy, it was not surprising that the overall survival advantage of irinotecan was somewhat less than in the previous study. Nevertheless, both achieved the clinical trial objective for patients with advanced disease, which was improvement in overall survival. Since 1998, irinotecan has been the standard second-line therapy for 5-FU refractory patients with advanced colorectal cancer in the United States and much of the world. Combination Chemotherapy Given irinotecan s single-agent activity and its different mechanism of action compared to 5-FU, combinations of these agents, typically also with leucovorin, were assessed in phase I and II trials. Of several regimens that were developed, one used bolus 5-FU and leucovorin for 4 weeks out of 6, with irinotecan also administered on the same days.[16] In another regimen, infusional 5-FU was administered with biweekly irinotecan treatment.[17] Using these regimens, two phase III prospective randomized controlled trials evaluated the combination of 5-FU, leucovorin, and irinotecan vs 5-FU and leucovorin alone. The first of these pivotal trials compared bolus 5-FU, leucovorin, and irinotecan with bolus 5-FU and leucovorin alone.[18] A third arm of irinotecan alone was also included. More than 200 patients were entered into each study arm. The primary end point was progression-free survival. Results showed that the combination was superior in terms of response rates, time to tumor progression, and overall survival rates.[18] Response rates were 39%, 21%, and 18% with combination treatment, 5-FU/leucovorin, or irinotecan, respectively; this was highly significant in favor of the combination. Time to tumor progression (7.0 vs 4.3 months; P =.004) and median survival (14.8 vs 12.6 months; P =.042) were also significantly improved with the combination, compared with 5-FU/leucovorin alone. Once again, the available data suggest that these improvements were achieved without a substantial decrement in overall quality of life or increased toxicity.[19] The second pivotal trial of combination chemotherapy with irinotecan compared two different regimens of infusional 5-FU and leucovorin (either the AIO or the de Gramont regimen).[20] Irinotecan was administered weekly or biweekly according to the 5-FU schedule. This trial also demonstrated improved response rate, time to tumor progression, and median survival for patients receiving the irinotecan combination. Median survival, the most important end point, was 17.4 months with the combination vs 14.1 months with fluorouracil and leucovorin (P =.032). Page 3 of 7

4 A combined survival analysis of these two trials was recently presented at the American Society of Clinical Oncology (ASCO) meeting.[21] Combined survival for the irinotecan/5-fu/leucovorin regimen was 15.9 months, and for the nonirinotecan regimen, 13.3 months (P =.003; survival hazard ratio, 0.79). Notably, a significant proportion of patients in both trials who were assigned to 5-FU and leucovorin alone subsequently received second-line irinotecan. Despite this crossover, a survival advantage was maintained, suggesting that sequential chemotherapy for advanced colorectal cancer may not be as effective as combination first-line treatments. Analyses have also been undertaken to determine which patients benefit most from combination chemotherapy.[22] Preliminary results suggest that all patients benefit, but that those with normal performance status and lactate dehydrogenase levels have the greatest improvement in overall survival compared with that achieved with 5-FU and leucovorin. Preliminary results of a cost-effectiveness analysis done in the United Kingdom also suggested that combination chemotherapy was more cost-effective than 5-FU and leucovorin.[23] Taken together, these data suggest that combination chemotherapy represents a new standard of care for patients with advanced colorectal cancer. In the United States, the combination used is 5-FU, leucovorin, and irinotecan, as approved by the U.S. Food and Drug Administration (FDA) Oncology Drugs Advisory Committee (ODAC) in March 2000.[19] Oxaliplatin Oxaliplatin is another nonfluoropyrimidine therapy that is available in many countries. Oxaliplatin is a platinum derivative whose main mechanism of action is the formation of DNA adducts. The carrier ligands for this compound are bulkier and more cytotoxic than those of cisplatin (Platinol) or carboplatin (Paraplatin), and oxaliplatin activity in tumor cell lines suggests a broad spectrum of activity, including in colorectal cancer.[24] As a single agent, oxaliplatin has demonstrated response rates similar to those of 5-FU or irinotecan, in both previously treated or untreated patients.[25] The primary unique toxicity of oxaliplatin appears to be neurotoxicity. Because oxaliplatin and 5-FU appear to have synergistic activity in tumor cell lines, many trials of oxaliplatin have been in combinations with 5-FU and leucovorin. Furthermore, many of the studies were conducted in Europe, so the regimens typically included infusional, rather than bolus, 5-FU with leucovorin. Results of a comparative trial of the de Gramont 5-FU and leucovorin regimen vs the same regimen with biweekly oxaliplatin added were recently reported.[26] The overall objective response rate was significantly higher with oxaliplatin added (49% vs 21.9%; P <.001). As with the irinotecan-containing combination, progression-free survival also significantly improved with the combination regimen; however, overall survival was not significantly different (15.9 vs 14.7 months; P =.13). Although a significant survival advantage was obtained when these data were adjusted for performance status, organ involvement, and baseline alkaline phosphatase level, the unadjusted survival did not show a clear benefit for the combination. For this reason, the combination was not approved for first-line therapy in the United States when first presented to the ODAC in March 2000.[19] Results of a second supportive trial, which used chronomodulated drug therapy, also demonstrated a higher response rate for the combination of oxaliplatin, 5-FU, and leucovorin, but no significant difference in overall survival.[27] There are many possible, post hoc explanations for the lack of significant survival advantage in these trials, including use of crossover therapy, aggressive surgical salvage therapy, and an infusional fluorouracil control arm that may have been superior to bolus therapy. Clearly, additional oxaliplatin trials are needed, particularly in the United States. A current trial design will recruit patients who have failed first-line 5-FU, leucovorin, and irinotecan and randomly assign them to receive infusional 5-FU and leucovorin alone, oxaliplatin alone, or infusional 5-FU and leucovorin with oxaliplatin. Based on current US regulatory standards, the primary study goal would be to establish a survival advantage for second-line oxaliplatin-containing regimens, similar to the end point that led to the Page 4 of 7

5 widespread use of irinotecan as second-line therapy in the United States. The previously described combination chemotherapy trials demonstrated response rates ranging from 34% to 51%, progression-free survivals from 6.7 to 9.3 months, and overall survivals from 14.0 to 19.4 months. These represent significant incremental improvements over traditional 5-FU approaches in the management of patients with metastatic colorectal cancer. Future Directions Based on results of these combination trials, 5-FU plus leucovorin has largely been abandoned as the control arm for clinical trials in the United States and abroad. For example, the NCCTG trial N9741, originally designed as a six-arm trial with the Mayo Clinic 5-FU and leucovorin regimen as the standard, was recently modified to compare 5-FU, leucovorin, and irinotecan (weekly) vs the de Gramont regimen of 5-FU, leucovorin, oxaliplatin (biweekly), vs oxaliplatin plus irinotecan (every 3 weeks). Thus, three different combination approaches will be directly compared. Whether any combination is superior for large patient groups is still uncertain, although a regimen s benefits and toxicities may differ in various patient populations based on sensitivity to each drug in a combination. Preliminary results have been reported of a French trial in which patients were randomly assigned to receive the de Gramont 5-FU and leucovorin regimen with either oxaliplatin or irinotecan, with a planned crossover approach.[28] The response rates have been equivalent for the two regimens, although longer follow-up will be required to assess survival differences. Triple combinations of fluoropyrimidines, irinotecan, and oxaliplatin are being tested in phase I and II trials to ascertain whether such approaches may be preferable in advance disease patients or in the adjuvant setting. Although available data suggest that first-line combination therapy is superior to single-agent treatment, this has not been optimally defined. In addition, the optimal treatment duration for patients with metastatic colorectal cancer is still not clear. Typically, chemotherapy is continued in responding patients; this was relatively easy with fluoropyrimidines, which are not associated with cumulative toxicity or secondary malignancies. However, cumulative neurotoxicity, myelosuppression, and other late toxicities may limit the total dose of newer agents such as oxaliplatin or irinotecan for patients in the advanced disease and adjuvant settings. Conclusion Although overall survival remains the gold standard for assessing therapeutic efficacy, the role of salvage surgery in patients with metastatic colorectal cancer remains to be defined, both in terms of its increased use in patients receiving combination chemotherapy and its effect on median survival in the clinical trial setting. In this regard, colorectal cancer is relatively unique in that patients with pulmonary and hepatic metastases may be treated with curative, ablative approaches in combination with systemic therapy. The increased efficacy of combination chemotherapy also raises the bar for median survival, so that very large trials would be required to detect improved outcomes when testing new agents. Furthermore, patients with metastatic colorectal cancer are not a homogeneous group in terms of prognosis or sensitivity to chemotherapy. Markers of prognosis, such as thymidylate synthase, allelic loss on chromosome 18, and microsatellite instability, may become useful in the advanced disease and adjuvant settings.[29] In addition, several markers of drug resistance and sensitivity that remain to be prospectively validated in large-scale trials have been identified. These include thymidylate synthase levels, dihydropyridine dehydrogenase (DPD) levels, and genetic polymorphisms that may predict resistance or increased toxicity to irinotecan or oxaliplatin. When fluoropyrimidine therapy was the only available modality of treatment, the identification of sensitive or resistant patients would simply lead to either a treatment or no-treatment approach. With two new agents available for patients with colorectal cancer, however, the ability to select patients for more- or less-intensive therapy, based on tumor sensitivity or resistance, will be a major step forward in the management of this disease. Page 5 of 7

6 References: 1. Ansfield F, Klotz J, Nealon T, et al: A phase III study comparing the clinical utility of four regimens of 5-fluorouracil: A preliminary report. Cancer 39(1):34-40, Advanced colorectal cancer meta-analysis project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10(6): , Buroker TR, O Connell MJ, Wieand HS, et al: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12(1):14-20, Poon MA, O Connell MJ, Mortal CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with metastatic colorectal carcinoma. J Clin Oncol 7(10): , de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15(2): , Cunningham D, Zalcberg JR, Rath U, et al: Final results of a randomised trial comparing Tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. Ann Oncol 7(9): , Labianca R, Pancera G, Barni S, et al: Biochemical modulation of fluoropyrimidines: The GISCAD studies. GISCAD (Italian group for the study of digestive tract cancer). Adv Exp Med Biol 339: , Seifert P, Baker LH, Reed ML, et al: Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36(1): , Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16(1): , Lokich J: Infusional 5-FU: Historical evolution, rationale, and clinical experience. Oncology (Huntington) 12(10 suppl 7):12-22, Ardalan B, Chua L, Tian EM, et al: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9(4): , Schmoll HJ, Köhne CH, Lorenz M, et al: Weekly 24h infusion of high-dose (HD) 5-fluorouracil (5-FU/24h) with or without leucovorin (FA) vs. bolus 5-FU/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): A randomized phase III study of the EORTC GITCCG and the AIO (abstract 935). Proc Am Soc Clin Oncol 19:241a, Conti JA, Kemeny NE, Saltz LB, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14(3): , Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352(9138): , Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352(9138): , Saltz LB, Kanowitz J, Kemeny NE, et al: Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 14(11): , Page 6 of 7

7 17. Vanhoefer U, Harstrick A, Kohne CH, et al: Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 17(3): , Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343(13): , FDA Website: ODAC minutes, March Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355(9209): , Saltz LB, Douillard JY, Pirotta N, et al: Combined analysis of two phase III randomized trials comparing irinotecan (C), fluorouracil (F), leucovorin (L) vs. F alone as first-line therapy of previously untreated metastatic colorectal cancer (MCRC) (abstract 938). Proc Am Soc Clin Oncol 19:242a, Knight RD, Miller LL, Pirotta N, et al: First-line irinotecan (C), fluorouracil (F), leucovorin (L) especially improves survival (OS) in metastatic colorectal cancer (MCRC) patients (PT) with favorable prognostic indicators (abstract 991). Proc Am Soc Clin Oncol 19:255a, Cunningham D, Falk S, Jackson DL, et al: Irinotecan and infusional 5-fluorouracil as first-line treatment of metastatic colorectal cancer: Improved survival and cost-effective compared with infusional 5-FU (abstract 981). Proc Am Soc Clin Oncol 19:253a, Chaney RE, Taamma A, Cvitkovic E: Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 9(10): , Cvitkovic E, Bekradda M: Oxaliplatin: A new therapeutic option in colorectal cancer. Semin Oncol 26(6): , de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: , Giacchetti S, Perpoint B, Zidani R, et al: Phase III randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1): , Tournigand C, Louvet C, Andre T, et al: FOLFIRI followed by FOLFOX or FOLFOX followed by FOLFIRI in metastatic colorectal cancer: Which is the best sequence? Safety and preliminary efficacy results of a randomized phase III study (abstract 949). Proc Am Soc Clin Oncol 19:245a, Hill MJ: Molecular and clinical risk markers in colon cancer trials. Eur J Cancer 36(6): , Source URL: Links: [1] [2] Page 7 of 7

Integrating Oxaliplatin into the Management of Colorectal Cancer

Integrating Oxaliplatin into the Management of Colorectal Cancer Integrating Oxaliplatin into the Management of Colorectal Cancer HANS-JOACHIM SCHMOLL, a JIM CASSIDY b a Martin-Luther-University Halle-Wittenberg, Halle, Germany; b University of Aberdeen, Aberdeen, UK

More information

Original article. E. Mitry 1 *, J.-Y. Douillard 2, E. Van Cutsem 3, D. Cunningham 4, E. Magherini 5, D. Mery-Mignard 5, L. Awad 5 & P.

Original article. E. Mitry 1 *, J.-Y. Douillard 2, E. Van Cutsem 3, D. Cunningham 4, E. Magherini 5, D. Mery-Mignard 5, L. Awad 5 & P. Original article Annals of Oncology 15: 1013 1017, 2004 DOI: 10.1093/annonc/mdh267 Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients

More information

Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD

Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant

More information

Review. A. Di Leo 1 *, M. Buyse 2 & H. Bleiberg 1. Introduction. Design and main results of the trials

Review. A. Di Leo 1 *, M. Buyse 2 & H. Bleiberg 1. Introduction. Design and main results of the trials Review Annals of Oncology 15: 545 549, 2004 DOI: 10.1093/annonc/mdh127 Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical

More information

Current Status of Adjuvant Therapy for Colorectal Cancer

Current Status of Adjuvant Therapy for Colorectal Cancer Review Article [1] May 01, 2004 By Michael J. O connell, MD [2] Adjuvant therapy with chemotherapy and/or radiation therapy in addition to surgery improves outcome for patients with high-risk carcinomas

More information

Original article. Introduction

Original article. Introduction Original article Annals of Oncology 13: 716 720, 2002 DOI: 10.1093/annonc/mdf091 Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the

More information

/m 2 Oxaliplatin 85 1 Q2W 1-3 Leucovorin Q2W 5-FU Q2W 5-FU Q2W

/m 2 Oxaliplatin 85 1 Q2W 1-3 Leucovorin Q2W 5-FU Q2W 5-FU Q2W 癌症診療指引33 Adjuvant therapy of colon cancer mfolfox6 Oxaliplatin 85 1 Q2W 1-3 FOLFOX4 Oxaliplatin 85 1 Q2W 9 Leucovorin 200 1-2 Q2W 5-FU 400 1-2 Q2W 5-FU 600 1-2 Q2W FLOX Oxaliplatin 85 1,15,29 Q8W 4 Leucovorin

More information

Management of Advanced Colorectal Cancer in Older Patients

Management of Advanced Colorectal Cancer in Older Patients Review Article [1] April 15, 2005 By Stuart M. Lichtman, MD, FACP [2] Many elderly individuals have substantial life expectancy, even in the setting of significant illness. There is evidence to indicate

More information

Chemotherapy of colon cancers

Chemotherapy of colon cancers Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having

More information

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution

More information

療指引 34 Adjuvant Therapy of Colon Cancer

療指引 34 Adjuvant Therapy of Colon Cancer 療指引 34 Adjuvant Therapy of Colon Cancer mfolfox6 Oxaliplatin 85 1 Q2W 1~3, 10 FLOX Oxaliplatin 85 1,15,29 Q8W 4 Leucovorin 500 1,8,15,22,29,35 Q8W 5-FU 500 1,8,15,22,29,35 Q8W Capecitabine Capecitabine

More information

Cytotoxic Chemotherapy for Advanced Colorectal Cancer

Cytotoxic Chemotherapy for Advanced Colorectal Cancer Review Article [1] November 02, 2005 By Scott Kopetz, MD [2] and Paulo M. Hoff, MD, FACP [3] Several developments in the past few years have incrementally progressed the field and provided additional insights

More information

Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination

Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination Clinical Report Chemotherapy 2002;48:94 99 Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination N.B. Tsavaris a A. Polyzos b K. Gennatas c

More information

Oral Fluoropyrimidine-Based Combination Therapy in Gastrointestinal Cancer

Oral Fluoropyrimidine-Based Combination Therapy in Gastrointestinal Cancer Oral Fluoropyrimidine-Based Combination Therapy in Gastrointestinal Cancer Review Article [1] January 0, 001 By Udo Vanhoefer, MD [] and Hans Jochen Wilke, MD [3] Significant emphasis has been placed recently

More information

Targeted Therapies in Metastatic Colorectal Cancer: An Update

Targeted Therapies in Metastatic Colorectal Cancer: An Update Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab

More information

Jonathan Dickinson, LCL Xeloda

Jonathan Dickinson, LCL Xeloda Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy

More information

Key words: advanced colorectal cancer, metastatic, irinotecan, 5-fluorouracil, leucovorin.

Key words: advanced colorectal cancer, metastatic, irinotecan, 5-fluorouracil, leucovorin. Original Article 297 Decreasing Dosage of Irinotecan, 5-Flurouracil (5-FU) and Leucovorin (LV) in the Treatment of Advanced and /or Metastatic Colorectal Cancer: A Phase II Study Jen-Seng Huang, MD; Cho-Li

More information

Understanding predictive and prognostic markers

Understanding predictive and prognostic markers Understanding predictive and prognostic markers Professor Aimery de Gramont Chairman of ARCAD Foundation and GERCOR, Paris FRANCE Understanding predictive and prognostic markers Aimery de Gramont Prognostic

More information

Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy

Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Valencia May Program 20-21st 2016 Prague May 22-23rd 2014 Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical

More information

Advances in Chemotherapy of Colorectal Cancer

Advances in Chemotherapy of Colorectal Cancer Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre

More information

大腸直腸癌 抗癌藥物治療指引 討論日期 團隊討論 : 105 年 10 月 19 日 三院討論 : 105 年 12 月 7 日 團隊確認 : 106 年 1 月 25 日 核備日期 : 106 年 4 月 18 日

大腸直腸癌 抗癌藥物治療指引 討論日期 團隊討論 : 105 年 10 月 19 日 三院討論 : 105 年 12 月 7 日 團隊確認 : 106 年 1 月 25 日 核備日期 : 106 年 4 月 18 日 大腸直腸癌 抗癌藥物治療指 討論日期 團隊討論 : 05 年 0 月 9 日 三院討論 : 05 年 2 月 7 日 團隊確認 : 06 年 月 25 日 核備日期 : 06 年 4 月 8 日 Adjuvant Therapy of Colon Cancer mfolfox6 參考文獻 -3 Oxaliplatin 85 Q2W 2 Leucovorin 400 Q2W 2 5-FU 400 Q2W

More information

Roche setting the standards of cancer care Oncology Event for Investors, June 19

Roche setting the standards of cancer care Oncology Event for Investors, June 19 Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time

More information

MP Laboratory Testing to Allow Area Under the Curve (AUC) Targeted 5- Flourouracil (5-FU) Dosing for Patients Administered 5-FU for Cancer

MP Laboratory Testing to Allow Area Under the Curve (AUC) Targeted 5- Flourouracil (5-FU) Dosing for Patients Administered 5-FU for Cancer MP 2.04.56 Laboratory Testing to Allow Area Under the Curve (AUC) Targeted 5- Flourouracil (5-FU) Dosing for Patients Administered 5-FU for Cancer Medical Policy Section Medicine Issue 12:2013 Original

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

Therapy for Metastatic Colorectal Cancer

Therapy for Metastatic Colorectal Cancer Therapy for Metastatic Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Learning Objectives Key

More information

What s New in Colon Cancer? Therapy over the last decade

What s New in Colon Cancer? Therapy over the last decade What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-

More information

State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan

State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival

More information

Original article. Introduction

Original article. Introduction Original article Annals of Oncology 14: 1106 1114, 2003 DOI: 10.1093/annonc/mdg288 A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic

More information

Toxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -

Toxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools - Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -

More information

NICE Health Technology Re-appraisal. Submission of the British Association of Surgical Oncology- The Association for Cancer Surgery

NICE Health Technology Re-appraisal. Submission of the British Association of Surgical Oncology- The Association for Cancer Surgery NICE Health Technology Re-appraisal The use of irinotecan, oxaliplatin and raltitrexed in the treatment of advanced colorectal cancer (review of guidance No. 33) Submission of the British Association of

More information

Adjuvant treatment Colon Cancer

Adjuvant treatment Colon Cancer ESMO Preceptorship Colorectal Cancer, October 2016 Singapore Adjuvant treatment Colon Cancer Claus-Henning Köhne University Clinic for Onkology und Haematology Oldenburg, Germany Aim of the lecture Adjuvant

More information

RECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER

RECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER RECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER SUNAKAWA, Y, 1 BEKAIISAAB, T, 2 AND STINTZING, S. 3 SELECTED HIGHLIGHTS

More information

Adjuvant therapy in colon cancer: which treatment in 2005?

Adjuvant therapy in colon cancer: which treatment in 2005? Annals of Oncology 16 (Supplement 4): iv69 iv73, 2005 doi:10.1093/annonc/mdi911 Adjuvant therapy in colon cancer: which treatment in 2005? F. Di Costanzo* & L. Doni Medical Oncology Unit, Department of

More information

ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine

ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000

More information

Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors

Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors Symposium article Annals of Oncology 14 (Supplement 2): ii25 ii29, 2003 DOI: 10.1093/annonc/mdg725 Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors

More information

S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m B a y e r

S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m B a y e r EXPERTS KNOWLEDGE SHARE with Prof. Köhne, Dr. Modest and Dr. Vecchione Madrid (Spain) Sunday September 10 th 2017 S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m

More information

Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal patients in the adjuvant setting

Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal patients in the adjuvant setting ORIGINAL ARTICLE CAPOX AND mfolfox6 DOSE INTENSITY AND CLINICAL OUTCOMES IN STAGE III CRC, Mamo et al. Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal

More information

trial update clinical

trial update clinical clinical trial update by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UMPC Cancer Centers In order to provide the most up-to-date and efficacious care to their patients, oncologists must

More information

Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials

Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials Original article Annals of Oncology 15: 1330 1338, 2004 doi:10.1093/annonc/mdh344 Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis

More information

Disclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -

Disclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools - Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis

More information

OWa 22 80) :IEZ

OWa 22 80) :IEZ Clinical Study Report: 20025409 Part 2 Date: 22 September 2008 OWa 22 80) 06 --- :IEZ Page 1 SYNOPSIS Name of the Sponsor: Name of Finished Product: Name of Active Ingredient: Immunex Corporation Panitumumab

More information

Type Days HRG Procurement 1 Cost and Volume Delivery 1 Day case. Weekly for 30 weeks. 1-14inc Capecitabine 1250mg/m² twice daily

Type Days HRG Procurement 1 Cost and Volume Delivery 1 Day case. Weekly for 30 weeks. 1-14inc Capecitabine 1250mg/m² twice daily Colorectal - Adjuvant Standard adjuvant therapy for Duke's C Day(s) Drug Dose Route Comments and high risk Duke's B Colorectal cancer 5-FU/FA Weekly 1 Folinic acid 50mg IV IV Bolus injection via fast running

More information

ORIGINAL ARTICLE. M. Bakogeorgos, G. Mountzios, G. Kotsantis, P. Economopoulou, N. Fytrakis, N. Kentepozidis. Summary.

ORIGINAL ARTICLE. M. Bakogeorgos, G. Mountzios, G. Kotsantis, P. Economopoulou, N. Fytrakis, N. Kentepozidis. Summary. JBUON 2013; 18(3): 629-634 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Chemotherapy compliance, tolerance and efficacy in elderly and non-elderly

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND

More information

Adjuvant/neoadjuvant systemic treatment of colorectal cancer

Adjuvant/neoadjuvant systemic treatment of colorectal cancer 5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico

More information

Hepatic arterial infusion pump chemotherapy for colorectal liver metastases: an old technology in a new era

Hepatic arterial infusion pump chemotherapy for colorectal liver metastases: an old technology in a new era Curr Oncol, Vol. 21, pp. e116-121; doi: http://dx.doi.org/10.3747/co.21.1592 HAI PUMP CHEMOTHERAPY FOR CRC METASTASIS REVIEW ARTICLE Hepatic arterial infusion pump chemotherapy for colorectal liver metastases:

More information

Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer

Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Axel Grothey, M.D., Professor of Oncology, Clinical and Translational Science Division of Medical Oncology Mayo Clinic, Rochester,

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer Alan Venook. doi: /theoncologist

Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer Alan Venook. doi: /theoncologist Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer Alan Venook The Oncologist 2005, 10:250-261. doi: 10.1634/theoncologist.10-4-250 The online version of this article, along with

More information

The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice

The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice Editorial The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice Marwan Fakih Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive

More information

INTRODUCTION. Jpn J Clin Oncol 2005;35(9) doi: /jjco/hyi140. Gil Medical Center, Incheon, Korea

INTRODUCTION. Jpn J Clin Oncol 2005;35(9) doi: /jjco/hyi140. Gil Medical Center, Incheon, Korea Oxaliplatin, Folinic Acid and 5-Fluorouracil (FOLFOX-4) Combination Chemotherapy as Second-line Treatment in Advanced Colorectal Cancer Patients with Irinotecan Failure: A Korean Single-center Experience

More information

ANTICANCER RESEARCH 26: (2006)

ANTICANCER RESEARCH 26: (2006) Clinical Impact of Adjuvant Chemotherapy on Patients with Stage III Colorectal Cancer: l-lv/5fu Chemotherapy as a Modified RPMI Regimen is an Independent Prognostic Factor for Survival TSUKASA HOTTA, KATSUNARI

More information

Medicinae Doctoris. One university. Many futures.

Medicinae Doctoris. One university. Many futures. Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All

More information

FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell Italia Meridionale (GOIM)

FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell Italia Meridionale (GOIM) Annals of Oncology 16 (Supplement 4): iv56 iv60, 2005 doi:10.1093/annonc/mdi909 FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell Italia Meridionale (GOIM) E.

More information

Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection

Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection Original article Annals of Oncology 15: 568 573, 2004 DOI: 10.1093/annonc/mdh134 Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after

More information

Curative treatment strategies for colorectal

Curative treatment strategies for colorectal EVALUATING DRUGS FOR COLORECTAL CANCER: RECENT CLINICAL TRIALS Robert J. Ignoffo, PharmD ABSTRACT Until the late 1990s, fluorouracil (FU) plus leucovorin (LV) was the standard adjuvant therapy for stage

More information

ONCOLOGY LETTERS 2: , 2011

ONCOLOGY LETTERS 2: , 2011 ONCOLOGY LETTERS 2: 241-245, 2011 Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following

More information

Reference No: Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review:

Reference No: Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review: Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Biliary Tract Cancer (BTC) Dr Colin Purcell, Consultant Medical Oncologist on behalf of the GI Oncologists Group, Cancer

More information

GASTRIC & PANCREATIC CANCER

GASTRIC & PANCREATIC CANCER GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org

More information

(5-fluorouracil 5-FU) [ ] FOLFOXIRI FOLFOXIRI. [DOI] /j.issn

(5-fluorouracil 5-FU) [ ] FOLFOXIRI FOLFOXIRI. [DOI] /j.issn 248 2016 3 1 41 3 FOLFOXIRI 21 [ ] FOLFOXIRI 21 FOLFOXIRI 150mg/m 2 d 1 85mg/m 2 d 1 200mg/m 2 d 1 5-2800mg/m 2 48h 2 1 3 4 42.9%(9/21) 8 (38.1%) 1 (4.8%)3 4.8%(1 ) 4 98.5% 93.4% 5-97.6% 14 (66.7%) 6 (28.6%)

More information

CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER

CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER Dr Elizabeth Smyth Royal Marsden, UK ESMO Gastric Cancer Preceptorship Valencia 2017 IMPORTANT CONSIDERATIONS WHEN TREATING ADVANCED GASTRIC CANCER Short OS Pain

More information

Irinotecan. Class:Camptothecin. Indications : _Cervical cancer. _CNS tumor. _Esophageal cancer. _Ewing s sarcoma. _Gastric cancer

Irinotecan. Class:Camptothecin. Indications : _Cervical cancer. _CNS tumor. _Esophageal cancer. _Ewing s sarcoma. _Gastric cancer Irinotecan Class:Camptothecin Indications : _Cervical cancer _CNS tumor _Esophageal cancer _Ewing s sarcoma _Gastric cancer _Nonsmall cell lung cancer _Pancreatic cancer _Small cell lung cancer _Colorectal

More information

clinical practice guidelines

clinical practice guidelines Annals of Oncology 21 (Supplement 5): v93 v97, 2010 doi:10.1093/annonc/mdq222 Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment E. Van Cutsem 1, B. Nordlinger 2 & A. Cervantes

More information

Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer

Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of

More information

Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough?

Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough? Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough? Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA 1 Disclosure Ad Board: Genentech Honorarium:

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT of the clinical trial data for this outcome. Therefore, perc considered that the cost-effectiveness of cetuximab plus FOLFIRI would be at the higher end of the EGP s range of best estimates. Therefore,

More information

Conflicts of Interest GI Malignancies: An Update on Current Treatment Options

Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of

More information

Surgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14

Surgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14 Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced

More information

The role of Maintenance treatment Appropriate endpoints according to ESMO consensus

The role of Maintenance treatment Appropriate endpoints according to ESMO consensus ESMO Preceptorship Programme Colorectal Cancer Singapore-October 20-22 2016 JY Douillard, MD, PhD, CMO ESMO The role of Maintenance treatment Appropriate endpoints according to ESMO consensus MAINTENANCE

More information

OVERALL CLINICAL BENEFIT

OVERALL CLINICAL BENEFIT cetuximab plus FOLFIRI to convert unresectable liver metastatses to resectable, perc confirmed that neither the FIRE-3 study nor the CRYSTAL study were designed to assess resectability and, in the absence

More information

J Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION VOLUME 25 NUMBER 18 JUNE 20 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Weekly Infusional High-Dose Fluorouracil (), Plus Folinic Acid (/FA), or /FA Plus Biweekly Cisplatin in Advanced

More information

Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From

Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From Four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03,

More information

discontinuation of the most toxic agent [4]. Wojciech Rogowski 1, Violetta Sulżyc-Bielicka 2 Introduction

discontinuation of the most toxic agent [4]. Wojciech Rogowski 1, Violetta Sulżyc-Bielicka 2 Introduction We still do not know whether the presently used protocol of the firstline palliative treatment of disseminated colorectal cancer (FOLFOX/ FOLFIRI protocol) allows maximization of therapeutic response and

More information

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS)

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann,

More information

Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS

Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver

More information

Disclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer

Disclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer Disclosures Colorectal Cancer Update GAFP November 2006 Robert C. Hermann, MD Georgia Center for Oncology Research and Education Northwest Georgia Oncology Centers, PC WellStar Health System Marietta,

More information

Phase I study of postoperative radiotherapy with concomitant weekly irinotecan, 5- fluorouracil and folinic acid in locally advanced rectal cancer.

Phase I study of postoperative radiotherapy with concomitant weekly irinotecan, 5- fluorouracil and folinic acid in locally advanced rectal cancer. Journal of BUON 9: 255-261, 2004 2004 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Phase I study of postoperative radiotherapy with concomitant weekly irinotecan, 5- fluorouracil and

More information

Materials and Methods

Materials and Methods RESEARCH ARTICLE Comparative Analysis of the Efficacy and Safety of Oxaliplatin Plus 5-Fluorouracil/Leucovorin (Modified FOLFOX6) with Advanced Gastric Cancer Patients having a Good or Poor Performance

More information

STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER

STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical

More information

Evaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant Therapy of Locally Advanced Rectal Cancer

Evaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant Therapy of Locally Advanced Rectal Cancer Efficacy of Modified De Gramont and FOLFOX4 Regimens for Locally Advanced Rectal Cancer RESEARCH COMMUNICATION Evaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant

More information

The efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different line setting*

The efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different line setting* Chinese-German J Clin Oncol DOI 10.1007/s10330-014-1295-2 April 2014, Vol. 13, No. 4, P169 P173 The efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different

More information

Advances in gastric cancer: How to approach localised disease?

Advances in gastric cancer: How to approach localised disease? Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation

More information

Lipoplatin monotherapy for oncologists

Lipoplatin monotherapy for oncologists Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE MERCK SERONO LTD. SINGLE TECHNOLOGY APPRAISAL SUBMISSION: ERBITUX (CETUXIMAB) FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER. - 1 - Contents

More information

Prof. Dr. med. Hans-Joachim Schmoll Biography

Prof. Dr. med. Hans-Joachim Schmoll Biography Prof. Dr. med. Hans-Joachim Schmoll Biography PubMed N publications: 445 Cumulative Impact factor: 1697 Web of Science Citation factor (h; Hirsch): 71 N Citations/year: 2017 1645 Short-CV Since 4 decades,

More information

Appendix E - Summary form Oxaliplatin and capecitabine for the adjuvant treatment of colon cancer table of consultee comments

Appendix E - Summary form Oxaliplatin and capecitabine for the adjuvant treatment of colon cancer table of consultee comments Oxaliplatin and capecitabine for the adjuvant treatment of colon cancer table of consultee comments Section Consultees Comments Action Objective Roche RCP RCP As far as capecitabine is concerned, the objective

More information

Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto

Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Milano 05.10.2018 Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Salvatore Corallo U.O.C. Oncologia Medica IRCCS Istituto Nazionale dei Tumori Milano CRC in elderly patients

More information

New Options in Metastatic Colorectal Cancer. Jeffrey A. Bubis, DO, FACOI, FACP Fleming Island Baptist South Palatka

New Options in Metastatic Colorectal Cancer. Jeffrey A. Bubis, DO, FACOI, FACP Fleming Island Baptist South Palatka New Options in Metastatic Colorectal Cancer Jeffrey A. Bubis, DO, FACOI, FACP Fleming Island Baptist South Palatka 4 th most frequently diagnosed CA in the US 2 nd leading cause of CA death in the US Incidence

More information

Opinion 17 October 2012

Opinion 17 October 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 17 October 2012 VECTIBIX 20 mg/ml, concentrate for solution for infusion B/1 vial of 5 ml (CIP code: 3400957181857)

More information

Adjuvant therapy in older adults: controversies and challenges - Colorectal cancer -

Adjuvant therapy in older adults: controversies and challenges - Colorectal cancer - International Society of Geriatric Oncology Lisbon October 23 rd 25t h 2014 Adjuvant therapy in older adults: controversies and challenges - Colorectal cancer - Claus-Henning Köhne Klinik für Onkologie

More information

Panel Two: Evidence for Use of Maintenance Therapy

Panel Two: Evidence for Use of Maintenance Therapy Panel Two: Evidence for Use of Maintenance Therapy Evidence for Use of Maintenance Therapy Richard L. Schilsky University of Chicago Comprehensive Cancer Center What is maintenance therapy? The continued

More information

Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009

Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif

More information

Comparison of first-line bevacizumab in combination with mfolfox6 or XELOX in metastatic colorectal cancer

Comparison of first-line bevacizumab in combination with mfolfox6 or XELOX in metastatic colorectal cancer JBUON 2015; 20(2): 460-467 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Comparison of first-line bevacizumab in combination with mfolfox6 or

More information

NCCP Chemotherapy Regimen

NCCP Chemotherapy Regimen QUASAR (Modified) Fluorouracil (370mg/m 2 ) and Folinic Acid (50mg) Weekly INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Treatment of metastatic colorectal cancer C18 00428a Adjuvant treatment of

More information

DALLA CAPECITABINA AL TAS 102

DALLA CAPECITABINA AL TAS 102 DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu

More information

Does it matter which chemotherapy regimen you partner with the biologic agents?

Does it matter which chemotherapy regimen you partner with the biologic agents? Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential

More information

Bevacizumab is currently licensed for the following indication relevant for this NICE review:

Bevacizumab is currently licensed for the following indication relevant for this NICE review: Roche Executive Summary Context Bevacizumab (Avastin) is a humanized (93% human) murine monoclonal antibody which binds to and neutralizes VEGF, a powerful pro-angiogenic glycoprotein produced by both

More information

Horizon Scanning Technology Briefing. Cetuximab (Erbitux) for metastatic colorectal cancer. National Horizon Scanning Centre.

Horizon Scanning Technology Briefing. Cetuximab (Erbitux) for metastatic colorectal cancer. National Horizon Scanning Centre. Horizon Scanning Technology Briefing National Horizon Scanning Centre Cetuximab (Erbitux) for metastatic colorectal cancer December 2006 This technology summary is based on information available at the

More information